In a report released today, Vamil Divan from Guggenheim maintained a Buy rating on Insmed, with a price target of $207.00. Claim 55% Off TipRanks. Unlock powerful investing tools ...
Travere Therapeutics spent the first half of 2026 converting a single approved medicine into a broader commercial and pipeline story. A rare-disease drugmaker built around FILSPARI, its treatment for ...
Travere Therapeutics Inc. company and executive profile by Barron's. View the latest TVTX company infomation and executive bios.
Today, the American Kidney Fund (AKF) and the IgA Nephropathy Foundation announce the creation of a new resource for IgA nephropathy patients and their loved ones: the IgA nephropathy patient ...
Vera Therapeutics Inc. research and ratings by Barron's. View VERA revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.
NVS wins full FDA approval for Fabhalta in IgA nephropathy after phase III data shows slower kidney function decline, ...
With combination therapies and multiple treatment options available for patients, nephrology is in a “therapeutic revolution, ...
The Alport syndrome market is expected to witness significant growth over the coming years, driven by advancements in genetic diagnostics, increasing disease awareness, and the introduction ...
Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on July 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 41,600 ...
June 2026 saw drug development in oncology and neurology continue and biotech deals over small molecules and RNA therapies ...
The first half of 2026 saw the FDA approve 5 notable first-in-class therapies across obesity, AML, kidney disease, hearing loss, and bladder cancer. The first half of 2026 brought a steady stream of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results